In our study, immune cell secreted IL-2 was attenuated by HuR-overexpression in ccRCC cells and dramatically stimulated by MS-444 treatment, indicating an unrecognized role of HuR inhibitors in augmenting the immune response through downregulation of CMTM6-PD-L1. Here, ELAVL1 is linked to nonpapillary renal cell carcinoma.